Home » Newsletters » BioWorld Science

BioWorld Science

July 18, 2003

View Archived Issues

Cinnamaldehyde derivative CB-403 exerts antitumor effect through cell cycle arrest

Further preclinical evaluation of FM-VP4

Novel lipid-lowering TRbeta1-selective agonists described by BMS

CS-747 prevents cerebral and peripheral arterial occlusive diseases in rats

Pharmacodynamics and pharmacokinetics of C3 and RO-14 in monkeys

Prochlorperazine more effective than divalproex sodium in acute migraine

Spotlight on Shiga toxin

Effective treatment of chronic anal fissures reported with topical nifedipine

Biological effects described for emfilermin in advanced cancer patients

CV Therapeutics patent covers new adenosine A2A antagonists

Pfizer claims novel NK2 antagonists for use in urinary incontinence and pain

Novel NF-kB activation inhibitors with antitumor and antiinflammatory activity

Yamanouchi researchers describe new mGluR1 modulators and their use

NHE-3 inhibitors in early development at Merck KGaA

Roche presents new prodrugs of Ro-63-8695 with improved bioavailability

Novel CCR3 receptor antagonists identified by Toray and Yamanouchi team

AstraZeneca reports CCR1 modulators with potassium channel-blocking activity

New GnRH antagonists in Takeda development pipeline

Potent, selective and orally active thrombin inhibitor in development at Servier

Antithrombotic effects described for PAR-1 antagonist in guinea pig model

Farnesyltransferase inhibitor ABT-100 shows significant clinical potential

FDA approves Zyprexa combination for acute manic episodes

SIGA and TransTech discover potential anti-SARS drug

E.C. awards Aplidin orphan drug status

BMS and Otsuka submit sNDA for Abilify

Phase II safety and biomarker trial of AGIX-4207 reports findings in RA

ALT-711 shows efficacy but fails to meet endpoints in SAPPHIRE and SILVER trials

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 22, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 22, 2026.
Cell/gene therapy sector now sustainable; China competition mounting
BioWorld
There was an upbeat message for cell and gene therapy companies in the 2026 industry update presented as the J.P. Morgan Healthcare Conference opened on Monday,...
Neurotrimin unveiled as marker in intellectual disability
BioWorld Science
Neurotrimin (NTM) is a member of the IgLON family, the disruption of which has been tied to emotional learning deficits and anxiety-like behavior in animal...
Abbvie snags PD-1/VEGF bispecific in potential $5B Remegen deal
BioWorld
With rumors regarding a couple of potential mega-mergers making the rounds, the week of the annual J.P. Morgan Healthcare Conference kicked off with the official...